pubmed.ncbi.nlm.nih.gov

Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody - PubMed

️Wed Jan 01 2014

Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody

David Hersi Smith et al. Sci Rep. 2014.

Abstract

Platinum chemotherapy remains part of standard therapies in the management of a variety of cancers. Severe side effects and a high degree of resistance to platinum drugs have led numerous researchers to search for predictive biomarkers, which could aid in identifying patients that are the most likely to respond to therapy. The ERCC1-ERCC4 endonuclease plays a critical role in the repair of platinum-DNA damage and has widely been studied in relation to sensitivity to platinum chemotherapy. The standard method to evaluate ERCC1 protein expression is through the use of immunohistochemistry with monoclonal antibody 8F1, an antibody that was recently found to bind an unrelated protein. The present study determines the specificity of a novel antibody, monoclonal antibody 4F9, and presents a method to evaluate ERCC1 expression in colorectal tumor specimens. Using relevant cell lines as controls, the specificity of antibody 4F9 was tested by immunoblotting, immunohistochemistry and immunofluorescence. Scoring guidelines to aid in the evaluation of ERCC1 tumor expression were developed and evaluated in archival formalin-fixed paraffin embedded colorectal cancer specimens. Antibody 4F9 was found to be specific by all methods applied and it was possible to evaluate the ERCC1 expression in the majority (85%) of colorectal cancer tumor specimens.

PubMed Disclaimer

Conflict of interest statement

Disclosures/Conflicts of interest: David Hersi Smith and Sussie Steen Jensen are employed at Dako A/S. Ib Jarle Christensen is an external consultant for Dako A/S. The remaining authors have no disclosures or conflicts of interest.

Figures

**Figure 1. Testing the specificity of anti-ERCC1 antibody 4F9.**
(A) Cropped western blot of protein lysates from Colo-205 and XP2YO. (B) Cropped western blot of protein lysates from Colo-205 with and without 8 μM oxaliplatin. (C) Immunohistochemical staining of paraffin-embedded Colo-205 and XP2YO cells. (D) Detection of ERCC1 and γ-H2AX in Colo-205 chamber slide cultures by immunofluorescence. (E) Immunohistochemical staining of parallel tonsil sections in presence and absence of peptide corresponding to the antibody 4F9 epitope. A germinal center in the absence (left) and presence of epitope peptide at 1 μgml⁻¹ (middle) and 10 μgml⁻¹ (right).

**Figure 2. Graphical representations of results from fixation study.**
Comparisons between selected cell populations with an external tonsil reference.

**Figure 3. Immunohistochemical staining of a stage III CRC tumor specimen.**
(A): Ganglion cells. (B): Tumor cells. (C): Crypt epithelium. The applied scoring guidelines require a comparison of tumor cells (B) with ganglion cells (strongest intensity is reference for score 3) (A) and crypt epithelium (weakest intensity is reference for score 1) (C). The tumor consists of cells producing staining intensities similar to ganglion cells, as well as cells that stain weaker, but stronger than crypt epithelium (i.e. moderate). Therefore, the final score of this tumor was 2–3, which was reported as ‘ERCC1 high – homogenous'.

Cited by

Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma.
Ötvös R, Szulkin A, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, Hjerpe A, Székely L, Dobra K. Ötvös R, et al. Genes Cancer. 2015 Mar;6(3-4):119-128. doi: 10.18632/genesandcancer.56. Genes Cancer. 2015. PMID: 26000095 Free PMC article.
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.
Abdel-Fatah TMA, Ali R, Sadiq M, Moseley PM, Mesquita KA, Ball G, Green AR, Rakha EA, Chan SYT, Madhusudan S. Abdel-Fatah TMA, et al. Cancers (Basel). 2019 Aug 10;11(8):1149. doi: 10.3390/cancers11081149. Cancers (Basel). 2019. PMID: 31405143 Free PMC article.
A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer.
Oishi T, Sasaki Y, Tong Y, Chen L, Onodera T, Iwasa S, Udo E, Furusato B, Fujimori H, Imamichi S, Honda T, Bessho T, Fukuoka J, Ashizawa K, Yanagihara K, Nakao K, Yamada Y, Hiraoka N, Masutani M. Oishi T, et al. Glob Health Med. 2021 Aug 31;3(4):226-235. doi: 10.35772/ghm.2021.01001. Glob Health Med. 2021. PMID: 34532603 Free PMC article.
Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.
Matuszczak M, Salagierski M. Matuszczak M, et al. Int J Mol Sci. 2020 May 9;21(9):3360. doi: 10.3390/ijms21093360. Int J Mol Sci. 2020. PMID: 32397531 Free PMC article. Review.
Undefined familial colorectal cancer and the role of pleiotropism in cancer susceptibility genes.
Dobbins SE, Broderick P, Chubb D, Kinnersley B, Sherborne AL, Houlston RS. Dobbins SE, et al. Fam Cancer. 2016 Oct;15(4):593-9. doi: 10.1007/s10689-016-9914-4. Fam Cancer. 2016. PMID: 27356891 Free PMC article.

References

1. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C. & Parken D. M. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. (2010) (Date of access: 31/7/2013).
1. Colucci G. et al. Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23, 4866–4875 (2005). - PubMed
1. Woynarowski J. M. et al. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol. 58, 920–927 (2000). - PubMed
1. Rabik C. A. & Dolan M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9–23 (2007). - PMC - PubMed
1. Martin L. P., Hamilton T. C. & Schilder R. J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 14, 1291–1295 (2008). - PubMed

Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody - PubMed